Biotech · Private company · Research Triangle Park, NC, US
T3D Therapeutics, Inc.
Track this companyFree. Adds T3D Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- T3D-959Phase 3 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 15mg T3D-959Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg T3D-959Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 45 mg T3D-959Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease SubjectsPHASE2_PHASE3 · NOT_YET_RECRUITING · started Oct 26, 2026ClinicalTrials.gov NCT06964230 · fetched Nov 12, 2026
- Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD SubjectsPHASE2 · COMPLETED · started Mar 1, 2021ClinicalTrials.gov NCT04251182 · fetched Nov 12, 2026
NIH awards2
- Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959Fiscal year 2025 · $203.8KNIH RePORTER 5R44AG082580-03 · fetched Nov 12, 2026
- Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959Fiscal year 2024 · $1MNIH RePORTER 5R44AG082580-02 · fetched Nov 12, 2026